Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fuzzyjr

Rank: Vice President [?]

Points: 5268 [?]

Votes: 36 Score: 3.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

in response to

Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

KOO-KOO2

posted on Sep 25, 2024 02:26PM

"13.333 Million common shares to ZCC. The Proceeds for continuing oncology clinical development and for RVX apabatelone commercializing efforts"

Same old dog & pony show - help rvx? If they got all of the money they would barely pay off Eversana let alone move the Science forward in any company.

im sick of this slow bleed , the only thing he's taking care of is him self.

I will sell my 100k + shares for a buck Canadian. If anyone wants them PM me & we will get it done.

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply